Fractyl Health
Market cap $12.8M 13.3M shares (10-Q, Nov 2, 2026) × $0.965 close Nov 17, 2026
Most recent annual filing: 2026-01-15
- Fractyl corporate financing4Q 2026/1Q 2027Fractyl corporate financing, 4Q 2026/1Q 2027, routine
- Revita filinglate 4Q 2026Revita filing, late 4Q 2026, notable
- Revita pivotal topline1Q 2027Revita pivotal topline, 1Q 2027, major
- 2023 Notes covenant corporate updatelate 1Q 20272023 Notes covenant corporate update, late 1Q 2027, routine
- Company-wide corporate update2Q 2027Company-wide corporate update, 2Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
Rejuva
AAV-delivered pancreatic gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones (GLP-1, GIP, PYY, amylin, glucagon). Modular platform using AAV9 vectors with tissue-restricted insulin promoter-driven transgene expression, delivered via proprietary endoscopic device directly to the pancreas.
Targets: GLP-1, GIP, PYY, amylin
Discontinued (3)
- Revita — Type 2 Diabetes · Strategic Reprioritization announced January 31, 2025; investment in Revita for T2D paused including REVITALIZE-1 study
- Rejuva — Type 2 Diabetes · strategic deprioritization; seeking strategic alternatives
- Rejuva — Obesity · strategic deprioritization; seeking strategic alternatives
Capital (as filed)
- Cash
- $31.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$15.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $31.5M cash, runway Q2 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (13)
- 2026-11-13 UPDATE: Fractyl Health (GUTS) - The Covenant Clock Beats the Data Clock 🔒 Paid
- 2026-10-22 UPDATE: Fractyl Health (GUTS) - The Moonshot Gets Cut 🔒 Paid
- 2026-10-16 UPDATE: Fractyl Health (GUTS) - The Pivotal Hit. The Stock Imploded. 🔒 Paid
- 2026-10-01 UPDATE: Fractyl Health (GUTS) - The Split Is Locked 🔒 Paid
- 2026-09-11 UPDATE: Fractyl Health (GUTS) - The September 9 Deadline Came and Went 🔒 Paid
- 2026-08-11 UPDATE: Fractyl Health (GUTS) - The Going Concern Arrives
- 2026-07-15 UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered (Randomized Edition) 🔒 Paid
- 2026-06-04 UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered 🔒 Paid
- 2026-05-12 UPDATE: Fractyl Health (GUTS) - The Moonshot Gets a Clinic 🔒 Paid
- 2026-03-29 UPDATES: Fractyl Health (GUTS) - Insiders Buys 🔒 Paid
- 2026-02-28 UPDATE: Fractyl Health (GUTS) - The Clock is Set 🔒 Paid
- 2026-01-30 UPDATE: Fractyl Health (GUTS) - The Mixed Data Crash (6-Mo Readout) 🔒 Paid
- 2026-01-07 Fractyl Health (GUTS): Scientific Deep Dive for Revita® and Rejuva®
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (13 calls)
Every verdict Biotech Distilled has published on Fractyl Health, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-07 Speculative buy speculative Fractyl Health (GUTS): Scientific Deep Dive for Revita® and Rejuva® Strong mechanistic proof-of-concept and cleared financing overhang create favorable risk/reward for the next 12 months ahead of binary 2026 catalysts.
- 2026-01-30 Buy speculative UPDATE: Fractyl Health (GUTS) - The Mixed Data Crash (6-Mo Readout) The 70% stock drop appears to be an overreaction to small-n statistical noise; the underlying biology in the High Responder target group remains intact (p=0.004) and the company is financed through the H2 2026 pivotal readout.
- 2026-02-28 Buy core UPDATE: Fractyl Health (GUTS) - The Clock is Set Completion of REMAIN-1 randomization removes trial execution risk and confirms the company is funded through the early Q4 2026 pivotal readout without a dilutive raise.
- 2026-03-29 Buy core UPDATES: Fractyl Health (GUTS) - Insiders Buys CEO and CFO buying a combined 350,000 shares at $0.55–$0.57 on the day the trading window opened post-earnings signals strong insider conviction that the January sell-off was a structural overreaction, not a fundamental failure.
- 2026-05-12 Buy core UPDATE: Fractyl Health (GUTS) - The Moonshot Gets a Clinic Dutch CTA clearance for RJVA-001 confirms the gene therapy pipeline has real clinical optionality, the H2 2026 catalyst slate is now two-headed, and management pre-empted dilution fears by confirming Rejuva development is funded within existing runway.
- 2026-06-04 Buy core UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered REVEAL-1 12-month open-label data showing 100% of patients above the pivotal's responder threshold and ~78% of GLP-1 weight loss retained answers the durability question and provides a concrete read-through to the Q4 pivotal co-primary endpoint.
- 2026-07-15 Buy core UPDATE: Fractyl Health (GUTS) - The Durability Question, Answered (Randomized Edition) Randomized 12-month REMAIN-1 Midpoint data confirms durable efficacy with a dose-response gradient, and favorable FDA De Novo feedback materially de-risks the regulatory pathway ahead of the early Q4 pivotal readout.
- 2026-08-11 Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The Going Concern Arrives The formal going-concern qualification and $10M loan covenant floor shift the balance sheet from 'adequate' to 'adequate only if the data lands,' warranting a downgrade to speculative while the clinical thesis remains intact.
- 2026-09-11 Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The September 9 Deadline Came and Went The Nasdaq delisting is stayed by a Panel hearing request, keeping shares trading through the pivotal readout window, but a near-certain reverse split raises the bar for the Tranche B warrant financing and the position remains a lottery-ticket-sized bet.
- 2026-10-01 Speculative buy speculative UPDATE: Fractyl Health (GUTS) - The Split Is Locked The 1-for-12 reverse split is confirmed and largely cosmetic, the pivotal readout window has opened, and the ~$71M market cap against an estimated ~$28M cash prices in substantial failure risk while the science remains unchanged.
- 2026-10-16 Hold UPDATE: Fractyl Health (GUTS) - The Pivotal Hit. The Stock Imploded. The pivotal co-primary was met (p=0.0023) validating the mechanism, but the effect size came in at roughly half of what Midpoint implied and the balance sheet now outranks the biology — existing holders should wait to see who writes the financing check and on what terms before acting.
- 2026-10-22 Hold UPDATE: Fractyl Health (GUTS) - The Moonshot Gets Cut Dropping Rejuva and cutting 45% of staff halves the burn rate and extends runway past the 12-month readout, but a raise before launch still looks unavoidable and new money is better served waiting for the financing to set the dilution.
- 2026-11-13 Avoid UPDATE: Fractyl Health (GUTS) - The Covenant Clock Beats the Data Clock The loan covenant could breach by end of Q1 2027 — the same quarter as the 12-month readout — placing the secured lender ahead of common shareholders, the reverse split failed to cure Nasdaq compliance, and stockholders' equity is negative, making the capital structure the dominant risk for new and existing holders.
- Long call · opened Jan 7, 2026 at $25.08 · closed Nov 13, 2026 (flipped bearish (avoid)) at $0.904 · -96.4% vs XBI +19.1%
- Avoid call · opened Nov 13, 2026 at $0.904 · +6.7% vs XBI -3.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company completed randomization of the pivotal cohort in February 2026, with topline six-month data anticipated in the early fourth quarter of 2026.”
matched to Revita · topline data · since happened Oct 16, 2026
-
-
-
“Subject to site activation, we expect to dose the first patient with RJVA-001 and report preliminary data in the second half of 2026.”
matched to RJVA-001 · other -
“The Company completed randomization of the pivotal cohort in February 2026, with topline six-month data anticipated in the early fourth quarter of 2026.”
matched to Revita · topline data · since happened Oct 16, 2026
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (36)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseFractyl Health Reports Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with $31.5M cash, a tighter covenant clock, a failed Nasdaq compliance cure (stock fell back below $1.00 after 16 days above), and meaningful new commercial catalysts — CPT code 1122T effective January 1, 2027 and a CMS RAPID pathway decision expected in early January that could unlock Medicare coverage for Revita ahead of a potential 2028 launch.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 6, 2026ReleaseFractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
- Nov 6, 20268-KCurrent report: officer / director change
- Oct 30, 2026ReleaseFractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
- Oct 29, 2026ReleaseFractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
- Oct 22, 2026ReleaseFractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance→ BD updateSummary on the 8-K
- Oct 22, 20268-KCurrent report: exit / restructuring costs, officer / director change, other events · EX-99.1→ BD updateFractyl kills Rejuva internally, cuts 45% of staff, and loses its co-founder — but the burn drops to ~$8M/quarter and runway extends to Q2 2027, buying time for the De Novo filing and the 12-month pivotal readout that could still attract a strategic buyer.BD extracted 2 program updates from this document → GUTS pipeline
- Oct 16, 2026ReleaseFractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation→ BD updateSummary on the 8-K
- Oct 16, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe REMAIN-1 Pivotal readout (n=308) hit p=0.0023 — but the stock cratered 63% on the day. This is the thesis-defining data drop, and the market's reaction makes the post essential reading.BD extracted 1 program update from this document → GUTS pipeline
- Oct 1, 20268-KCurrent report: charter / bylaws / fiscal year→ BD updateThe 1-for-12 reverse split is confirmed and effective Friday after close — every 12 shares become 1, GUTS opens Monday at a split-adjusted price that, at today's $0.45 close, implies roughly $5.40 per new share, and the Tranche B warrants originally at $1.05 reset to ~$12.60, raising the bar the pivotal data must clear to trigger Fractyl's elegant non-dilutive financing path.
- Sep 24, 20268-KCurrent report: shareholder vote
- Sep 11, 20268-KCurrent report: listing notice→ BD updateThe September 9 Nasdaq deadline passed without compliance; Fractyl filed a Panel hearing request that automatically stays delisting — buying time for the early-Q4 pivotal readout, but a 1-for-5 to 1-for-15 reverse split is now on the ballot.
- Sep 9, 2026ReleaseFractyl Health to Participate in Upcoming September Investor Conferences
- Aug 24, 2026DEF 14AProxy statement
- Aug 20, 2026ReleaseFractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight MaintenanceBD extracted 1 program update from this document → GUTS pipeline
- Aug 10, 2026ReleaseFractyl Health Reports Second Quarter 2026 Financial Results and Business UpdatesBD extracted 1 program update from this document → GUTS pipeline
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 202610-QQuarterly report
- Aug 3, 2026ReleaseFractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026via aggregator
- Jul 22, 2026ReleaseFractyl Health to Participate in Upcoming Investor Eventsvia aggregator
- Jul 15, 2026ReleaseFractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuationvia aggregatorBD extracted 1 program update from this document → GUTS pipeline
- Jul 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 11, 20268-KCurrent report: shareholder vote
- Jun 4, 2026ReleaseFractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedurevia aggregator
- Jun 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 1, 2026ReleaseFractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategyvia aggregator
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- May 11, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Mar 24, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Mar 24, 202610-KAnnual report
- Mar 17, 20268-KCurrent report: listing notice
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Oct 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026PRE 14APRE 14A
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026SCHEDULE 13G/A13G amendment
- Apr 24, 2026ARSAnnual report to shareholders